Quarterly report pursuant to Section 13 or 15(d)

Discontinued Operations

v3.21.1
Discontinued Operations
3 Months Ended
Mar. 31, 2021
Discontinued Operations  
Discontinued Operations

9.    Discontinued Operations

The components of loss from discontinued operations as reported in our statements of operations were as follows:

 

 

 

 

 

 

    

Three months ended

 

 

March 31, 2020

(In thousands, except per share data)

 

 

  

Revenue:

 

 

  

Product revenue

 

$

210

 

 

 

 

Costs and expenses:

 

 

  

Cost of goods sold

 

 

171

Research and development

 

 

465

Selling, general and administrative

 

 

1,825

Total costs and expenses

 

 

2,461

Loss from discontinued operations

 

 

(2,251)

Other expense

 

 

 —

Net loss from discontinued operations

 

$

(2,251)

Basic and diluted net loss per common share from discontinued operations

 

$

(0.82)

Weighted average shares used in computing basic and diluted net loss per common share

 

 

2,755

 

The following table presents information related to assets and liabilities reported as discontinued operations in our balance sheet:

 

 

 

 

 

 

 

 

March 31, 

    

December 31,

 

2021

 

2020

(In thousands)

 

  

 

 

  

Prepaid expenses and other current assets

 

128

 

 

181

Discontinued operations – current assets

$

128

 

$

181

 

 

 

 

 

 

Accounts payable

$

1,518

 

$

1,515

Accrued clinical trials expenses

 

 9

 

 

80

Accrued sales allowances

 

57

 

 

61

Other accrued liabilities

 

309

 

 

304

Discontinued operations – current liabilities

$

1,893

 

$

1,960

 

During the three months ended March 31, 2020 we recognized non-cash stock-based compensation expenses of approximately $24,000 which is included in discontinued operations.